Aravive Inc.

0.9600-0.0400-4.00%Vol 294.19K1Y Perf -76.85%
Aug 9th, 2022 16:00 DELAYED
BID0.9481 ASK1.00
Open1.01 Previous Close1.00
Pre-Market- After-Market-
 - -  - -%
Target Price
16.25 
Analyst Rating
Strong Buy 1.00
Potential %
1.59K 
Finscreener Ranking
★★★★+     57.89
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     50.74
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.23
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.56 
Earnings Rating
Strong Sell
Market Cap29.30M 
Earnings Date
11th Aug 2022
Alpha-0.05 Standard Deviation0.29
Beta2.56 

Today's Price Range

0.94001.10

52W Range

0.79564.40

5 Year PE Ratio Range

-2.10-1.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
21.76%
1 Month
6.33%
3 Months
-20.00%
6 Months
-55.56%
1 Year
-76.85%
3 Years
-83.74%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARAV0.9600-0.0400-4.00
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-
-575.50
-563.90
-1 603.30
-
RevenueValueIndustryS&P 500US Markets
4.49M
0.16
29.60
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.53-0.62-16.98
Q04 2021-0.64-0.623.12
Q03 2021-0.42-0.53-26.19
Q02 2021-0.41-0.3514.63
Q01 2021-0.45-0.442.22
Q04 2020-0.52-0.2551.92
Q03 2020-0.42-0.66-57.14
Q02 2020-0.45-0.3228.89
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.62-19.23Negative
9/2022 QR-0.65-20.37Negative
12/2022 FY-2.45-17.79Negative
12/2023 FY-2.305.35Positive
Next Report Date11th Aug 2022
Estimated EPS Next Report-0.62
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume294.19K
Shares Outstanding30.52K
Shares Float21.69M
Trades Count1.04K
Dollar Volume305.17K
Avg. Volume86.78K
Avg. Weekly Volume94.44K
Avg. Monthly Volume71.94K
Avg. Quarterly Volume93.95K

Aravive Inc. (NASDAQ: ARAV) stock closed at 1 per share at the end of the most recent trading day (a 8.61% change compared to the prior day closing price) with a volume of 232.86K shares and market capitalization of 29.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Aravive Inc. CEO is Gail McIntyre.

The one-year performance of Aravive Inc. stock is -76.85%, while year-to-date (YTD) performance is -54.34%. ARAV stock has a five-year performance of %. Its 52-week range is between 0.7956 and 4.4, which gives ARAV stock a 52-week price range ratio of 4.56%

Aravive Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.66, a price-to-sale (PS) ratio of 5.78, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.57%, a ROC of -72.56% and a ROE of -84.94%. The company’s profit margin is -%, its EBITDA margin is -563.90%, and its revenue ttm is $4.49 Million , which makes it $0.16 revenue per share.

Of the last four earnings reports from Aravive Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. Aravive Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Aravive Inc. is Strong Buy (1), with a target price of $16.25, which is +1 592.71% compared to the current price. The earnings rating for Aravive Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aravive Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aravive Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.49, ATR14 : 0.08, CCI20 : 203.90, Chaikin Money Flow : -0.12, MACD : -0.02, Money Flow Index : 62.09, ROC : 7.53, RSI : 47.43, STOCH (14,3) : 77.31, STOCH RSI : 1.00, UO : 55.21, Williams %R : -22.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aravive Inc. in the last 12-months were: Fredric N. Eshelman (Option Excercise at a value of $455)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aravive Inc.

Aravive Inc is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company's lead candidate AVB-500 is developed as a targeted therapy against ovarian cancer.

CEO: Gail McIntyre

Telephone: +1 936 355-1910

Address: 3730 Kirby Drive, Houston 77010, TX, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

59%41%

Bearish Bullish

67%33%

TipRanks News for ARAV

Mon, 06 Jun 2022 10:35 GMT Analysts Offer Insights on Healthcare Companies: Aravive (ARAV), Oncternal Therapeutics (ONCT) and Curis (CRIS)

- TipRanks. All rights reserved.

Sat, 19 Mar 2022 09:08 GMT Aravive (ARAV) Gets a Buy Rating from BTIG

- TipRanks. All rights reserved.

News

Stocktwits